Rajkumari Mazumdar¹,², Juri Saikia¹,³ and Debajit Thakur¹
¹Microbial Biotechnology Laboratory, Life Sciences Division, Institute of Advanced Study in Science and Technology (IASST), Guwahati, India
²Department of Molecular Biology and Biotechnology, Cotton University, Guwahati, India
³Department of Biotechnology, Gauhati University, Guwahati, India

Part of the book: Infectious Diseases: From Prevention to Control

Abstract

Infectious diseases are illnesses caused by pathogenic microorganisms that enter our bodies from the outside. They can sometimes be caught by other people, the environment, animal contact, or insect bites. Some infections are so mild that we might not notice any symptoms, while others can be fatal. Existing and emerging infectious diseases pose significant challenges to public health outcomes around the globe. Pathogenic bacteria continue to be a severe health concern, causing many fatalities and hospitalizations yearly. Due to the development of new variants of drug-resistant pathogenic microorganisms, the treatment and immunization of infectious diseases have become even more challenging in recent years. Existing diagnostic techniques are inefficient because they lack speed and ultra-sensitivity. Therefore, novel therapeutic and diagnostic approaches are required. The primary goal of this study is to highlight current trends in antibiotic resistance as well as novel therapeutic prospects for future disease management and control advancements.

Keywords: infectious diseases, antimicrobial resistance, pathogenic bacteria, WHO, actinobacteria, antimicrobial peptides, nanoparticle

References

[1] Doron, S., and S. L. Gorbach. “Bacterial infections: overview.” International
Encyclopedia of Public Health (2008): 273.
[2] Barberis, Ilaria, Nicola Luigi Bragazzi, Lucia Galluzzo, and Mariano Martini. “The
history of tuberculosis: from the first historical records to the isolation of Koch’s
bacillus.” Journal of Preventive Medicine and Hygiene 58, no. 1 (2017): E9.
[3] Long, Richard, Maziar Divangahi, and Kevin Schwartzman. “Chapter 2:
Transmission and pathogenesis of tuberculosis.” Canadian Journal of Respiratory,
Critical Care, and Sleep Medicine 6, no. sup1 (2022): 22-32.
[4] Barnett, Richard. “Case histories Typhoid fever.” Lancet 388, no. 10059 (2016):
2467-2467.
[5] Organisation, W. H., https://www.vox.com/2020/6/17/21289483/coronavirus-covid-19-vaccine-vaccinations-measles-malaria-tuberculosis. 2020.
[6] Hutchings, Matthew I., Andrew W. Truman, and Barrie Wilkinson. “Antibiotics:
past, present and future.” Current Opinion in Microbiology 51 (2019): 72-80.
[7] Munita, Jose M., and Cesar A. Arias. “Mechanisms of antibiotic resistance.”
Microbiology Spectrum 4, no. 2 (2016): 4-2.
[8] World Health Organisation., The Global Burden of Disease: 2004 update. 2008.
[9] Murhekar, Manoj V., and CP Girish Kumar. “Health-care-associated infection
surveillance in India.” The Lancet Global Health 10, no. 9 (2022): e1222-e1223.
[10] Monegro, Alberto F., Vijayadershan Muppidi, and Hariharan Regunath. “Hospital
acquired infections.” In StatPearls [Internet]. StatPearls Publishing, 2020.
[11] World Health Organisation., Report on the Burden of Endemic Health Care Associated Infection Worldwide. 2011.
[12] World Health Organisation., Global Report on Infection Prevention and Control.
2022.
[13] Markwart, Robby, Hiroki Saito, Thomas Harder, Sara Tomczyk, Alessandro
Cassini, Carolin Fleischmann-Struzek, Felix Reichert, Tim Eckmanns, and
Benedetta Allegranzi. “Epidemiology and burden of sepsis acquired in hospitals and
intensive care units: a systematic review and meta-analysis.” Intensive Care
Medicine 46, no. 8 (2020): 1536-1551.
[14] Balakrishnan, Vijay Shankar. “WHO’s first global infection prevention and control
report.” The Lancet Infectious Diseases 22, no. 8 (2022): 1122.
[15] Tomczyk, Sara, Veronica Zanichelli, M. Lindsay Grayson, Anthony Twyman,
Mohamed Abbas, Daniela Pires, Benedetta Allegranzi, and Stephan Harbarth.
“Control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and
Pseudomonas aeruginosa in healthcare facilities: a systematic review and reanalysis
of quasi-experimental studies.” Clinical Infectious Diseases 68, no. 5 (2019): 873-884.
[16] Nguyen, M., and S. G. Joshi. “Carbapenem resistance in Acinetobacter baumannii,
and their importance in hospital‐acquired infections: a scientific review.” Journal of
Applied Microbiology 131, no. 6 (2021): 2715-2738.
[17] Fisher, Margaret C. Immunizations & Infectious Diseases: An Informed Parent’s
Guide. American Academy of Pediatrics, 2006.
[18] Murray, Christopher JL, Kevin Shunji Ikuta, Fablina Sharara, Lucien Swetschinski,
Gisela Robles Aguilar, Authia Gray, Chieh Han, Catherine Bisignano, Puja Rao,
Eve Wool, Sarah C Johnson et al. “Global burden of bacterial antimicrobial
resistance in 2019: a systematic analysis.” The Lancet 399, no. 10325 (2022): 629-655.
[19] De Simeis, Davide, and Stefano Serra. “Actinomycetes: A never-ending source of
bioactive compounds—An overview on antibiotics production.” Antibiotics 10, no.
5 (2021): 483.
[20] Sartelli, M., C. Hardcastle, T., Catena, F., Chichom-Mefire, A., Coccolini, F.,
Dhingra, S., Haque, M., Hodonou, A., Iskandar, K., Labricciosa, F. M., Marmorale,
C., Sall, I., & Pagani, L. “Antibiotic use in low and middle-income countries and the
challenges of antimicrobial resistance in surgery.” Antibiotics 9, no. 8 (2020): 497.
[21] Gandra, Sumanth, Gerardo Alvarez-Uria, Paul Turner, Jyoti Joshi, Direk
Limmathurotsakul, and H. Rogier van Doorn. “Antimicrobial resistance surveillance
in low-and middle-income countries: progress and challenges in eight South Asian
and Southeast Asian countries.” Clinical Microbiology Reviews 33, no. 3 (2020):
e00048-19.
[22] Limmathurotsakul, D., Dunachie, S., Fukuda, K., Feasey, N. A., Okeke, I. N.,
Holmes, A. H., Moore, C. E., Dolecek, C., van Doorn, H. R., Shetty, N., Lopez, A.
D., & Peacock, S. J. “Improving the estimation of the global burden of antimicrobial
resistant infections.” The Lancet Infectious Diseases 19, no. 11 (2019): e392-e398.
[23] Jonas, Olga B., Alec Irwin, Franck Cesar Jean Berthe, Francois G. Le Gall, and
Patricio V. Marquez. “Drug-resistant infections: a threat to our economic future
(Vol. 2): final report.” HNP/Agriculture Global Antimicrobial Resistance Initiative
(2017).
[24] Sandra Ponen, w.h.o., https://www.healthnavigator.org.nz/medicines/a/antibiotic resistance/#Overview. 2017.
[25] Reygaert, Wanda C. “An overview of the antimicrobial resistance mechanisms of
bacteria.” AIMS Microbiology 4, no. 3 (2018): 482.
[26] Andersson, Dan I., and Diarmaid Hughes. “Selection and transmission of antibiotic resistant bacteria.” Microbiology Spectrum 5, no. 4 (2017): 5-4.
[27] World Health Organization, WHO Publishes List of Bacteria for Which New
Antibiotics are Urgently Needed. 2017.
[28] Munkholm, L. and O. Rubin, The global governance of antimicrobial resistance: a
cross-country study of alignment between the global action plan and national action
plans. Globalization and Health, 2020. 16(1): p. 109.
[29] Zrnčić, S. N. J. E. Ž. A. N. A. “European Union’s Action Plan on Antimicrobial
Resistance and Implications for Trading Partners with Example of National Action
Plan for Croatia.” Asian Fish Sci. S 33 (2020): 75-82.
[30] Sader, Helio S., Paul R. Rhomberg, Andrew S. Fuhrmeister, Rodrigo E. Mendes,
Robert K. Flamm, and Ronald N. Jones. “Antimicrobial resistance surveillance and
new drug development.” In Open Forum Infectious Diseases, vol. 6, no.
Supplement_1, pp. S5-S13. US: Oxford University Press, 2019.
[31] Núñez-Núñez, M., Navarro, M. D., Palomo, V., Rajendran, N. B., del Toro, M. D.,
Voss, A., Sharland, M., Sifakis, F., Tacconelli, E., Rodríguez-Baño, J., Burkert, F.,
Carrara, E., von Cube, M., Drgona, L., Gilchrist, K., Goossens, H., Harbarth, S.,
Hequet, D., Jafri, H., … Zingg, W. “The methodology of surveillance for
antimicrobial resistance and healthcare-associated infections in Europe (SUSPIRE):
a systematic review of publicly available information.” Clinical Microbiology and
Infection 24, no. 2 (2018): 105-109.
[32] Gandra, Sumanth, Gerardo Alvarez-Uria, Paul Turner, Jyoti Joshi, Direk
Limmathurotsakul, and H. Rogier van Doorn. “Antimicrobial resistance surveillance
in low-and middle-income countries: progress and challenges in eight South Asian
and Southeast Asian countries.” Clinical Microbiology Reviews 33, no. 3 (2020):
e00048-19.
[33] World Health Organisation., Global antimicrobial resistance and use surveillance
system (GLASS) report: 2021.
[34] World Health Organisation., Global antimicrobial resistance surveillance system
(GLASS) report: early implementation 2017-2018. 2018.
[35] AMBIDEXTROUS, BEING. “Stewardship for the 21st century.” Thinking (2019).
[36] McGowan Jr, J. E., and D. N. Gerding. “Does antibiotic restriction prevent
resistance?.” New Horizons (Baltimore, Md.) 4, no. 3 (1996): 370-376.
[37] Singh, S., Menon, V. P., Mohamed, Z. U., Kumar, V. A., Nampoothiri, V., Sudhir,
S., Moni, M., Dipu, T. S., Dutt, A., Edathadathil, F., Keerthivasan, G., Kaye, K. S.,
& Patel, P. K. “Implementation and impact of an antimicrobial stewardship program
at a tertiary care center in South India.” In Open Forum Infectious Diseases, vol. 6,
no. 4, p. ofy290. US: Oxford University Press, 2019.
[38] Schuts, E. C., Hulscher, M. E. J. L., Mouton, J. W., Verduin, C. M., Stuart, J. W. T.
C., Overdiek, H. W. P. M., van der Linden, P. D., Natsch, S., Hertogh, C. M. P. M.,
Wolfs, T. F. W., Schouten, J. A., Kullberg, B. J., & Prins, J. M. “Current evidence
on hospital antimicrobial stewardship objectives: a systematic review and meta analysis.”
The Lancet Infectious Diseases 16, no. 7 (2016): 847-856.
[39] Cox, Janneke Arnoldine, Erika Vlieghe, Marc Mendelson, Heiman Wertheim, L.
Ndegwa, María Virginia Villegas, I. Gould, and G. Levy Hara. “Antibiotic
stewardship in low-and middle-income countries: the same but different?.” Clinical
Microbiology and Infection 23, no. 11 (2017): 812-818.
[40] ReAct Report, The World Needs New Antibiotics – So Why Aren’t They Developed.
2021.
[41] Davies, Julian. “Where have all the antibiotics gone?.” Canadian Journal of
Infectious Diseases and Medical Microbiology 17, no. 5 (2006): 287-290.
[42] Kållberg, Cecilia, Christine Årdal, Hege Salvesen Blix, Eili Klein, Elena M.
Martinez, Morten Lindbæk, Kevin Outterson, John-Arne Røttingen, and Ramanan
Laxminarayan. “Introduction and geographic availability of new antibiotics
approved between 1999 and 2014.” PloS One 13, no. 10 (2018): e0205166.
[43] Bawazir, Ali Mohammed Abdullah, and Manjula Shantaram Palaksha. “An
Implication Of Actinomycetes On Human Well-Being: A Review.” Int J Pharm
Pharm Sci (2019).
[44] World Health Organisation, Report on lack of new antibiotics threatens global
efforts to contain drug-resistant infections. 2020.
[45] Sharma, Priyanka, and Debajit Thakur. “Antimicrobial biosynthetic potential and
diversity of culturable soil actinobacteria from forest ecosystems of Northeast
India.” Scientific Reports 10, no. 1 (2020): 1-18.
[46] Thakur, D., A. Yadav, B. K. Gogoi, and T. C. Bora. “Isolation and screening of
Streptomyces in soil of protected forest areas from the states of Assam and Tripura,
India, for antimicrobial metabolites.” Journal de Mycologie Médicale 17, no. 4
(2007): 242-249.
[47] Miao, Vivian, and Julian Davies. “Actinobacteria: the good, the bad, and the ugly.”
Antonie Van Leeuwenhoek 98, no. 2 (2010): 143-150.
[48] Nguyen, Hue Thi, Anaya Raj Pokhrel, Chung Thanh Nguyen, Van Thuy Thi Pham,
Dipesh Dhakal, Haet Nim Lim, Hye Jin Jung, Tae-Su Kim, Tokutaro Yamaguchi,
and Jae Kyung Sohng. “Streptomyces sp. VN1, a producer of diverse metabolites
including non-natural furan-type anticancer compound.” Scientific Reports 10, no.
1 (2020): 1-14.
[49] Nair, Soumya, and Jayanthi Abraham. “Natural products from actinobacteria for
drug discovery.” In Advances in Pharmaceutical Biotechnology, pp. 333-363.
Springer, Singapore, 2020.
[50] Huan, Yuchen, Qing Kong, Haijin Mou, and Huaxi Yi. “Antimicrobial peptides:
classification, design, application and research progress in multiple fields.”
Frontiers in Microbiology (2020): 2559.
[51] Wang, Guangshun. “Database-guided discovery of potent peptides to combat HIV 1 or superbugs.”
Pharmaceuticals 6, no. 6 (2013): 728-758.
[52] Divyashree, Mithoor, Madhu K. Mani, Dhanasekhar Reddy, Ranjith Kumavath,
Preetam Ghosh, Vasco Azevedo, and Debmalya Barh. “Clinical applications of
antimicrobial peptides (AMPs): where do we stand now?.” Protein and Peptide
Letters 27, no. 2 (2020): 120-134.
[53] León-Buitimea, Angel, Cesar R. Garza-Cárdenas, Javier A. Garza-Cervantes, Jordy
A. Lerma-Escalera, and Jose R. Morones-Ramírez. “The demand for new
antibiotics: antimicrobial peptides, nanoparticles, and combinatorial therapies as
future strategies in antibacterial agent design.” Frontiers in Microbiology (2020):
1669.
[54] Zharkova, Maria S., Dmitriy S. Orlov, Olga Yu Golubeva, Oleg B. Chakchir, Igor
E. Eliseev, Tatyana M. Grinchuk, and Olga V. Shamova. “Application of
antimicrobial peptides of the innate immune system in combination with
conventional antibiotics—a novel way to combat antibiotic resistance?.” Frontiers
in Cellular and Infection Microbiology 9 (2019): 128.
[55] Akbari, Reza, Mojdeh Hakemi-Vala, Fatemeh Pashaie, Parvaneh Bevalian, Ali
Hashemi, and Kamran Pooshang Bagheri. “Highly synergistic effects of melittin
with conventional antibiotics against multidrug-resistant isolates of acinetobacter
baumannii and pseudomonas aeruginosa.” Microbial Drug Resistance 25, no. 2
(2019): 193-202.
[56] Li, C., Zhu, C., Ren, B., Yin, X., Shim, S. H., Gao, Y., Zhu, J., Zhao, P., Liu, C.,
Yu, R., Xia, X., & Zhang, L. “Two optimized antimicrobial peptides with
therapeutic potential for clinical antibiotic-resistant Staphylococcus aureus.”
European Journal of Medicinal Chemistry 183 (2019): 111686.
[57] Wang, Linlin, Chen Hu, and Longquan Shao. “The antimicrobial activity of
nanoparticles: present situation and prospects for the future.” International Journal
of Nanomedicine 12 (2017): 1227.
[58] Santos, C. L., A. J. R. Albuquerque, F. C. Sampaio, and D. Keyson. “Nanomaterials
with antimicrobial properties: applications in health sciences.” Microbial Pathogens
and Strategies for Combating Them: Science, Technology and Education. Volume
4, no. 2 (2013).
[59] Mazumdar, Rajkumari, and Debajit Thakur. “Therapeutic Applications of
Nanotechnology in the Prevention of Infectious Diseases.” In Emerging
Nanomaterials for Advanced Technologies, pp. 323-343. Springer, Cham, 2022.
[60] Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. del P.,
Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S.,
Habtemariam, S., & Shin, H. S. “Nano based drug delivery systems: recent
developments and future prospects.” Journal of Nanobiotechnology 16, no. 1
(2018): 1-33.
[61] Ramalingam, Baskaran, Thanusu Parandhaman, and Sujoy K. Das. “Antibacterial
effects of biosynthesized silver nanoparticles on surface ultrastructure and
nanomechanical properties of gram-negative bacteria viz. Escherichia coli and
Pseudomonas aeruginosa.” ACS Applied Materials & Interfaces 8, no. 7 (2016):
4963-4976.
[62] Nas, F. S., M. Ali, and A. Muhammad. “Application of nanomaterials as
antimicrobial agents: a review.” Archives of Nanomedicine 1, no. 3 (2018): 59-64.
[63] Sobhani, Zahra, Soliman Mohammadi Samani, Hashem Montaseri, and Elham
Khezri. “Nanoparticles of chitosan loaded ciprofloxacin: fabrication and
antimicrobial activity.” Advanced Pharmaceutical Bulletin 7, no. 3 (2017): 427.
[64] McMillan, JoEllyn, Elena Batrakova, and Howard E. Gendelman. “Cell delivery of
therapeutic nanoparticles.” Progress in Molecular Biology and Translational
Science 104 (2011): 563-601.